使用Revi系统治疗急迫性尿失禁的关键性OASIS研究:两年疗效与安全性结局
OASIS研究在151名女性中植入Revi胫神经调控系统,97名完成24个月评估,其中79%为治疗应答者(急迫性尿失禁发作减少≥50%),6、12、24个月应答率分别为78%、82%、79%,97%(88/91)满意,80%(78/97)感觉「好很多」或「非常好」,24个月内无器械或操作相关严重不良事件。
要点
- Revi系统是首个无需先前保守治疗失败即可使用的FDA清关植入式神经调控装置。
- 24个月时79%为治疗应答者,6、12、24个月应答率分别为78%、82%、79%,疗效持久。
- 97%(88/91)满意,80%(78/97)感觉「好很多」或「非常好」,24个月内无器械或操作相关严重不良事件。
核心结论
- 两年结果显示持久的疗效、高患者满意度和非常有利的安全性特征。
研究设计与样本
- OASIS(Overactive Bladder Stimulation System)研究,将Revi系统植入151名女性参与者。
- 主要疗效和安全性终点在6个月和12个月评估,之后参与者要么同意延长随访以长期评估治疗持久性和安全性,要么选择退出研究。
主要发现
- 97名参与者完成24个月评估,其中79%为治疗应答者(3天排尿日记显示急迫性尿失禁发作减少≥50%)。
- 6、12、24个月应答率分别为78%、82%、79%。
- 完成6个月和24个月评估的参与者在6个月访视时人口统计学和治疗结果相似。
- 97%(88/91)的参与者对治疗满意,80%(78/97)感觉「好很多」或「非常好」。
- 24个月内无器械或操作相关严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The BlueWind Medical Device, Revi, is a novel implantable tibial neuromodulation system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence (ie, overactive bladder wet). The Revi System is the first Food and Drug Administration-cleared implantable neuromodulation device which can be used without prior failure with more conservative treatment options. Two-year follow-up results of the OASIS (Overactive Bladder Stimulation System) study are presented. MATERIALS AND METHODS: The Revi System was implanted in 151 female participants. The primary efficacy and safety end points were assessed at 6 and 12 months, after which participants either consented to extend follow-up for long-term assessment of treatment durability and safety or they chose to exit the study. RESULTS: Ninety-seven participants completed the 24-month assessment, and of these, 79% were therapy responders (≥50% reduction in urgency urinary incontinence episodes, demonstrated on a 3-day voiding diary). Importantly, therapeutic response was durable, with comparable effectiveness at 6, 12, and 24 months (response rates of 78%, 82%, and 79%, respectively). Participants who completed both the 6- and 24-month assessment had similar demographics and treatment results at the 6-month visit, indicating that these results at 24 months are representative of the overall study population. In addition, high satisfaction and patient impression of improvement were reported, with 97% (88/91) of the participants satisfied with the therapy and 80% (78/97) feeling "much better" or "very much better." There were no serious adverse events related to the device or the procedure through 24 months. CONCLUSIONS: Two-year results demonstrate durable efficacy, high patient satisfaction, and a very favorable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03596671.
引用
- Heesakkers JPFA, Toozs-Hobson P, Sutherland SE, et al. Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence. J Urol. 2024. PMID: 39585851. doi:10.1097/JU.0000000000004328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。